Get the Stockscreener App
97.16
0.26%
-0.25
After Hours:
97.16
Incyte Corp stock is traded at $97.16, with a volume of 879.79K.
It is down -0.26% in the last 24 hours and up +0.43% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
See More
Previous Close:
$97.41
Open:
$97.3
24h Volume:
879.79K
Relative Volume:
0.59
Market Cap:
$19.41B
Revenue:
$5.36B
Net Income/Loss:
$1.43B
P/E Ratio:
13.74
EPS:
7.0718
Net Cash Flow:
$1.42B
1W Performance:
+1.94%
1M Performance:
+0.43%
6M Performance:
-4.80%
1Y Performance:
+50.61%
1-Day Range:
$96.04
$98.21
1-Week Range:
$94.10
$98.40
52-Week Range:
$63.51
$112.29
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
97.16 | 19.46B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Feb-05-26 | Initiated | H.C. Wainwright | Buy |
| Jan-20-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-08-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-03-25 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
INCYTE CORP (NASDAQ:INCY) Shows Rare Alignment of High Growth Momentum and Technical Breakout Setup - ChartMill
INCY Initiates Coverage On Bernstein -- Rating Set to Market Per - GuruFocus
How Incyte’s AI-Powered R&D Partnerships At Incyte (INCY) Has Changed Its Investment Story - Yahoo Finance
Bernstein initiates Incyte stock coverage with concerns on growth By Investing.com - Investing.com South Africa
Incyte (INCY) Coverage Initiated with Caution by Bernstein - GuruFocus
Bernstein initiates Incyte stock coverage with concerns on growth - Investing.com UK
Bernstein SocGen Group Starts Incyte (INCY) at Market Perform - StreetInsider
Incyte (NASDAQ: INCY) director exercises options and sells 15K shares - Stock Titan
Incyte stock price target maintained at $135 by H.C. Wainwright - Investing.com
Incyte and Genesis expand molecular AI collaboration - The Pharma Letter
Incyte Corp stock (US45337C1027): focus on latest Jakafi data and pipeline outlook - AD HOC NEWS
Incyte expands AI drug discovery pact with $120M funding boost - MSN
How Incyte’s (INCY) Opzelura Data and Edison AI Deal Could Reframe Its Risk Profile - simplywall.st
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Grants Equity Awards to New CFO Suketu Upadhyay - MyChesCo
Incyte (INCY) Expands AI Collaboration with Genesis Molecular - GuruFocus
Incyte (INCY) CMO granted 44,124 performance-based shares in Form 4/A - Stock Titan
Incyte (NASDAQ: INCY) awards 31,517 earned performance shares to R&D president - Stock Titan
Incyte (INCY) Expands AI Drug Discovery Partnership with Genesis Molecular AI - GuruFocus
Incyte gears up to report Q1 earnings: What can investors expect? - MSN
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery - Business Wire
Edison’s AI scientist to be embedded across Incyte discovery and development ops - The Pharma Letter
INCY Stock Price, Quote & Chart | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte stock (US45337C1027): AI partnership and pipeline keep biopharma story moving - AD HOC NEWS
[144] INCYTE CORP SEC Filing - Stock Titan
Incyte Reports Extended Opzelura Eczema Trial Results - MyChesCo
Incyte Stock: Analyst Estimates & Ratings - Yahoo Finance
Incyte partners with Edison Scientific on AI drug discovery - Investing.com
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development - Business Wire
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp stock (US45337C1027): Institutional buying draws fresh attention to the biotech group - AD HOC NEWS
Incyte Corporation $INCY Shares Purchased by Northwestern Mutual Wealth Management Co. - MarketBeat
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build - Yahoo Finance
Baker Bros. Advisors LP Increases Stake in Incyte Corp with Strategic Acquisition - GuruFocus
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte Corp stock (US45337C1027): Biopharma leader in oncology therapies - AD HOC NEWS
Dodge & Cox holds 12.25M Incyte shares (NASDAQ: INCY), a 6.2% stake - Stock Titan
FDA Approves Once-Daily Jakafi XR for Blood Disorders - MyChesCo
Swiss Life Asset Management Ltd Boosts Stake in Incyte Corporation $INCY - MarketBeat
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Associa - PharmiWeb.com
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress - BioSpace
Incyte to Present Pipeline Strategy at May Investor Conferences - MyChesCo
Baker Brothers and Incyte (INCY): 15,000-share option exercise detailed - Stock Titan
Baker Bros. funds exercise Incyte (NASDAQ: INCY) director stock options - Stock Titan
Incyte Corporation (INCY) Highlights Sustained Efficacy of Opzelura Through Week 24 - Insider Monkey
Incyte Appoints Suketu Upadhyay as Chief Financial Officer - MyChesCo
Incyte Reports Q1 Revenue Growth as Pipeline Advances - MyChesCo
Incyte's (NASDAQ:INCY) Promising Earnings May Rest On Soft Foundations - Yahoo Finance
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):